Clinical study of Bacteriophage Therapy for the treatment of secondary infections with carbapenem resistant Acinetobacter baumannii (CRAB) bacteria in COVID-19 patients
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Bacteriophage therapeutics-BiomX (Primary)
- Indications Acinetobacter infections
- Focus Therapeutic Use
- 18 Mar 2024 According to a BiomX media release, Adaptive Phage Therapeutics has been acquired and merged into BiomX
- 09 Nov 2020 New trial record
- 02 Nov 2020 According to an Phage Therapeutics media release, the company in collaboration with their collaborators Dr. Benjamin Chan, Yale University and Dr. Jonathan Koff from Yale University School of Medicine hope to provide nebulized therapy in addition to IV PhageBank™ therapy.